NCT05799209 is a NA clinical trial of Float Pool in Amphetamine-Type Substance Use Disorder, sponsored by Laureate Institute for Brain Research, Inc..

Who is sponsoring NCT05799209?

NCT05799209 is sponsored by Laureate Institute for Brain Research, Inc..

What drugs are being tested in NCT05799209?

Interventions in NCT05799209: Float Pool, Float Chair.

What condition does NCT05799209 study?

NCT05799209 studies Amphetamine-Type Substance Use Disorder.

Is NCT05799209 still recruiting?

NCT05799209 is currently status unknown. Last updated 6 October 2023.

Last reviewed 2023-10-06 · How we verify

NCT05799209

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Floatation-REST in Methamphetamine Use Disorder: A Pilot Study

Status unknown NA Last updated 6 October 2023

What this trial tests

NA trial testing Float Pool in Amphetamine-Type Substance Use Disorder in 100 participants. Status unknown.

Timeline

15 March 2022

Primary endpoint
1 August 2024

1 August 2024

Quick facts

Lead sponsor	Laureate Institute for Brain Research, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	100
Start date	15 March 2022
Primary completion	1 August 2024
Estimated completion	1 August 2024
Sites	1 location across United States

Drugs / interventions tested

Float Pool
Float Chair

Conditions studied

Amphetamine-Type Substance Use Disorder — all drugs for Amphetamine-Type Substance Use Disorder →

Sponsor

Laureate Institute for Brain Research, Inc.

Who can join

Adults 18 to 55, any sex, with Amphetamine-Type Substance Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This early-stage trial aims to examine the feasibility, tolerability, and safety of Floatation-REST (Reduced Environmental Stimulation Therapy) or an active comparison condition in 50 individuals receiving treatment for Amphetamine-Type Substance Use Disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Laureate Institute for Brain Research, Inc. trials

Trials by the same sponsor.

NCT06410196 — Mood and Decision-making in Methamphetamine Use Disorder · NA · recruiting
NCT06088732 — Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression · Phase 1, PHASE2 · recruiting
NCT06219681 — Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression · NA · terminated
NCT06004115 — Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression · Phase 4 · recruiting
NCT06486584 — Contingency Management for Problematic Behavior Reduction in the Community · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05799209 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laureate Institute for Brain Research, Inc.
Last refreshed: 6 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05799209.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing